Eli Lilly and Company (LLY)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	10,590,000	8,369,900	7,342,200	6,138,400	5,240,400	4,988,400	6,497,500	5,686,800	6,244,800	6,033,200	5,691,600	6,129,300	5,581,700	5,972,400	6,070,700	6,092,500	6,193,700	5,572,600	5,618,100	5,533,300
Total stockholders’ equity	US$ in thousands	14,192,100	14,240,000	13,562,000	12,812,200	10,771,900	11,220,400	11,063,800	11,190,400	10,649,800	10,070,100	8,544,700	9,330,800	8,979,200	7,757,000	6,444,400	6,898,700	5,641,600	4,826,900	4,092,900	3,078,800
ROE		74.62%	58.78%	54.14%	47.91%	48.65%	44.46%	58.73%	50.82%	58.64%	59.91%	66.61%	65.69%	62.16%	76.99%	94.20%	88.31%	109.79%	115.45%	137.26%	179.72%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $10,590,000K ÷ $14,192,100K
= 74.62%

Eli Lilly and Company's Return on Equity (ROE) has shown fluctuating trends over the periods from March 2020 to December 2024. The ROE started at a high of 179.72% in March 2020, indicating strong profitability relative to shareholders' equity. However, the ratio gradually decreased over the following quarters and years, reaching 44.46% in September 2023, reflecting a decline in profitability relative to the equity invested.

There was a slight recovery in the ROE in the subsequent periods, with the ratio increasing to 74.62% by December 2024. This improvement suggests that the company's profitability in generating returns for shareholders had started to strengthen again. Overall, the fluctuating ROE indicates varying levels of efficiency in utilizing equity to generate profits during the analyzed time frame. Investors and analysts may further investigate the factors impacting Eli Lilly and Company's ROE to gain deeper insights into the company's financial performance and prospects.